Erschienen in:
01.05.2011 | Clinical Research
Alloprosthetic Composite is a Suitable Reconstruction After Periacetabular Tumor Resection
verfasst von:
Davide Donati, MD, Claudia Di Bella, MD, Tommaso Frisoni, MD, Luca Cevolani, MD, Henry DeGroot, MD
Erschienen in:
Clinical Orthopaedics and Related Research®
|
Ausgabe 5/2011
Einloggen, um Zugang zu erhalten
Abstract
Background
Resection of a tumor of the pelvis is most disabling when the acetabulum is excised and a durable reconstruction of the defect is hard to achieve. All available methods are associated with frequent complications. Few large series have been published, and fewer have focused entirely on complete resections of the acetabulum. The use of an allograft-prosthetic composite allows customization on the operating table. However, while such composites restore anatomy and function of the pelvis the use of pelvic allografts is controversial and the durability is unknown.
Questions/purposes
We therefore examined (1) the frequency of allograft and prosthetic failure, (2) positive and negative factors influencing the survival of the allograft prosthetic composite, and (3) function of patients with this reconstruction.
Patients and Methods
We retrospectively evaluated 35 patients who had resection of the entire acetabulum and reconstruction with an allograft-prosthetic composite. Function was scored by the Musculoskeletal Tumor Society system. Followup in 24 survivors averaged 120 months (range, 61–188 months).
Results
Greater than 75% of the allografts were still in place at last followup, and the original prosthetic reconstruction was still in place in 56%. Infection was an important negative factor for allograft survival. The average functional score was 72%, with better mean scores for patients who had reconstruction with a stemmed cup and an artificial ligament (average 89%).
Conclusions
An allograft-prosthetic composite provides a versatile substitution of the pelvis and hip, with functional scores approximately 75% of normal.
Level of Evidence
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.